Sorevna Unveils Revolutionary Anti-Aging Face Cream

New York, NY, Oct. 12, 2024 (GLOBE NEWSWIRE) — Sorevna(R), one of the leading USA manufacturers and distributors of cruelty-free, organic skincare products, today announced the launch of its newest face cream, designed to address the specific concerns of aging skin through advanced moisturizing technology. Sorevna Anti-Aging Face Cream Building on the success of their […]

Mister Global 2024: A Historic Win for the Philippines and A New Era of Gentlemen with Essence

Bangkok, Thailand, Oct. 12, 2024 (GLOBE NEWSWIRE) — Mister Global 2024 Held in Bangkok on October 6th, 2024 by Thailand-based TPN Global Group, the event brought together 33 contestants from around the world, culminating in Corilla’s groundbreaking victory. A new tradition was also introduced this year, with the presentation of the Blazer of Fame, which

AILE Investors Have Opportunity to Lead iLearningEngines, Inc. Securities Fraud Lawsuit

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of iLearningEngines, Inc. (NASDAQ: AILE) between April 22, 2024 and August 28, 2024. Shareholders who want to serve as a lead plaintiff for the class must file their motions with the

STLA Deadline: STLA Investors Have Opportunity to Lead Stellantis N.V. Securities Fraud Lawsuit

Rosen Law Firm, a global investor rights law firm, remindspurchasers of securities of Stellantis N.V. (NYSE: STLA) between February 15, 2024 and July 24, 2024, both dates inclusive (the “Class Period”), of the importantOctober 15, 2024 lead plaintiff deadline. https://mma.prnewswire.com/media/405060/Rosen_Law_Logo.jpg So what: If you purchased Stellantis securities during the Class Period you may be entitled

Vasco & Co. brand Filet Royal Smoked Atlantic Salmon recalled due to Listeria monocytogenes

Product:Filet Royal Smoked Atlantic Salmon Issue:Food – Microbial contamination – Listeria Distribution:Quebec See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA) https://rt.newswire.ca/rt.gif?NewsItemId=C5538&Transmission_Id=202410120939CANADANWWEB______C5538&DateId=20241012 COMTEX_458736235/1005/2024-10-12T09:40:21

MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit

Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company’s initial public offering conducted between February 9 and 13, 2024 (the “IPO”), of the important November 25, 2024 lead plaintiff deadline. https://mma.prnewswire.com/media/405060/Rosen_Law_Logo.jpg So what: If you purchased Metagenomi stock you may

Does Utopia Exist? David Jeremiah Launches New Teaching Series and Book

Murder, theft, violence, war, natural disasters, illness, tyranny, lies-these are just a few of the things that fill the news and cause us anxiety. Despite the best efforts and good intentions of governments, churches, humanitarian organizations, and collectives like the United Nations and NATO, the world is still filled with evil and heartache. Sadly 92%

LLAP Investors Have Opportunity to Lead Terran Orbital Corporation Securities Fraud Lawsuit

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Terran Orbital Corporation (NYSE: LLAP) between August 15, 2023 and August 14, 2024, both dates inclusive (the “Class Period”), of the important November 26, 2024 lead plaintiff deadline. https://mma.prnewswire.com/media/405060/Rosen_Law_Logo.jpg So what: If you purchased Terran securities during the Class Period you

Rosen Law Firm Encourages Visa Inc. Investors to Inquire About Securities Class Action Investigation – V

https://mma.prnewswire.com/media/405060/Rosen_Law_Logo.jpg Why:Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Visa Inc. (NYSE: V) resulting from allegations that Visa may have issued materially misleading business information to the investing public. So What: If you purchased Visa securities you may be entitled to compensation

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis

First scientific presentation of previously announced data from Cohort 1 of the ongoing Phase 1b clinical trial evaluating low-dose LTI-03 (2.5 mg BID) in IPF, affirms positive trends in seven of the eight biomarkers evaluated, suggesting potential therapeutic effect Recently completed enrollment of Cohort 2 evaluating high-dose LTI-03 (5 mg BID) in mid-September; topline data

Scroll to Top